InMed Pharmaceuticals (INM) Emerging Growth Conference 72 summary

Research and development pipeline

• Three drug candidates in dermatology, ocular disease, and Alzheimer's, with a completed Phase II study in dermatology and preclinical programs in the other two areas.

• Focus on proprietary small molecule cannabinoid analogs targeting diseases with high unmet needs.

• Strong patent and IP position across molecules, manufacturing, and formulations.

• Two divisions: pharmaceutical R&D in Vancouver and BayMedica for large-scale cannabinoid manufacturing.

• BayMedica subsidiary generates steady, profitable revenue by supplying bioidentical cannabinoids to the health and wellness industry.

Alzheimer's disease program (INM-901)

• INM-901 is a small molecule with multiple mechanisms, including neural protection, neurogenesis, and reduced neural inflammation.

• Preclinical studies show behavioral improvements in animal models, with treated animals displaying more normal cognition and memory.

• Compound crosses the blood-brain barrier and may be orally delivered.

• Data from long-term animal studies expected mid-summer; additional studies planned to explore neural inflammation.

• Early external feedback suggests disease-modifying potential, with ongoing discussions for strategic partnerships.

Macular degeneration program (INM-089)

• INM-089 targets dry age-related macular degeneration (AMD), leveraging neuroprotective effects of cannabinoids.

• Preclinical data show preserved retinal function, improved photoreceptor activity, and reduced damaging deposits in animal models.

• Delivered via injection into the eye, following standard care for retinal diseases.

• Next steps include toxicology studies and advancing toward IND filing and human trials.

• Seeking partnerships with larger companies active in ocular disease.